1 unchanged sentence
Market Information
−Removed: Our common stock has traded on the NYSE American under the symbol “SYN” since February 16, 2012.
+Added: Our common stock has traded on the NYSE American under the symbol “TOVX’ since October 13, 2022.
+Added: Prior to October 13, 2022 our common stock traded under the symbol “SYN” since February 16, 2012.
Prior to February 16, 2012, our common stock traded under the symbol “AEN” since October 16, 2008.
5 unchanged sentences
The Series A Preferred Stock, none of which remains outstanding, ranked senior to the shares of our common stock and shares of our Series B Preferred Stock with respect to dividend rights and holders of Series A Preferred Stock were entitled to a cumulative dividend at the rate of 2.0% per annum, payable quarterly in arrears, as set forth in the Certificate of Designation of Series A Convertible Preferred Stock.
+Added: The Series C Preferred Stock and Series D Preferred Stock is entitled to receive dividends on an as-if-converted-to-common-Stock basis to and in the same form as dividends actually paid on shares of the Common Stock when, as and if such dividends are paid on shares of the common stock.
As of March 30, 2023, we had approximately 33 stockholders of record of our common stock.
3 unchanged sentences
Equity Compensation Plan Information
−Removed: See Part II–Item 12 under the heading “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters—Equity Compensation Plan Information” of this Annual Report on Form 10-K for equity compensation plan information.
+Added: See Part III–Item 12 under the heading “Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters—Equity Compensation Plan Information” of this Annual Report for equity compensation plan information.
Recent Sales of Unregistered Securities
−Removed: We did not sell any equity securities during the quarter ended December 31, 2021 in transactions that were not registered under the Securities Act, other than as previously disclosed in our filings with the SEC.
+Added: We did not sell any equity securities during the year ended December 31, 2022 in transactions that were not registered under the Securities Act, other than as previously disclosed in our filings with the SEC.
Issuer Purchases of Equity Securities
−Removed: There were no issuer purchases of equity securities during the year ended December 31, 2021.
+Added: On December 22, 2022, we repurchased an aggregate of 720,000 shares of our common stock, par value $0.001 (the “Common Stock”) from three founders of its subsidiary Theriva Biologics S.L.
+Added: (formerly known as VCN Biosciences S.L.) in a privately negotiated
+Added: transaction pursuant to the terms of a Share Repurchase Agreement (the “Share Repurchase Agreement”) entered into on December 20, 2022 with each of the Selling Stockholders.
+Added: Summary of the 2022 stock repurchase activity is as follows:
+Added: Total number of
+Added: shares purchased as
+Added: Maximum number of
+Added: part of publicly
+Added: shares that may yet be
+Added: Total number of
+Added: Average price paid
+Added: announced plans or
+Added: purchased under the
+Added: shares purchased
+Added: plans or programs
+Added: December 2022
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.